{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:59:41Z","timestamp":1761868781060,"version":"build-2065373602"},"reference-count":59,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To assess the cost\u2010effectiveness of dapagliflozin, a sodium\u2010glucose co\u2010transporter\u20102 (SGLT2) inhibitor, as an adjunct to insulin in adults with type 1 diabetes mellitus (T1DM) inadequately controlled by insulin alone in the UK setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cost\u2013utility analysis was conducted to compare dapagliflozin (5\u2009mg or 10\u2009mg) added to insulin versus insulin monotherapy (standard of care) over a lifetime horizon. Treatment efficacy and safety data were obtained from 52\u2010week results of the DEPICT\u20101 and DEPICT\u20102 trials and a network meta\u2010analysis of SGLT2 inhibitors in T1DM. Direct healthcare costs, life\u2010years, and quality\u2010adjusted life\u2010years (QALYs) were estimated from a UK payer perspective and discounted at 3.5% annually, using the Cardiff T1DM Model. Sensitivity analyses assessed uncertainty in estimated incremental cost\u2010effectiveness ratios (ICERs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Dapagliflozin 5\u2009mg was associated with gains of 0.23 life\u2010years and 0.42 QALYs, at an additional cost of \u00a34240 per person; corresponding to an ICER of \u00a310\u2009143 versus standard of care. For dapagliflozin 10\u2009mg, incremental life\u2010years, QALYs and costs were 0.24, 0.49 and \u00a32964, respectively; corresponding to an ICER of \u00a36103 versus standard of care. In probabilistic sensitivity analysis, ICER estimates fell below \u00a320\u2009000\/QALY in 78% to 90% of simulations. Cost\u2010effectiveness results were sensitive to changes in baseline patient characteristics and treatment effects on glycated haemoglobin; however, ICERs remained below \u00a320\u2009000.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>At cost\u2010effectiveness thresholds conventionally applied in the UK, dapagliflozin as an adjunct to insulin appears to be a cost\u2010effective treatment option for people with T1DM inadequately controlled by insulin alone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.13992","type":"journal-article","created":{"date-parts":[[2020,2,9]],"date-time":"2020-02-09T23:20:34Z","timestamp":1581290434000},"page":"1047-1055","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cost\u2010effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom"],"prefix":"10.1111","volume":"22","author":[{"given":"Hayley","family":"Bennett","sequence":"first","affiliation":[{"name":"Health Economics and Outcomes Research Ltd  Cardiff UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amarjeet","family":"Tank","sequence":"additional","affiliation":[{"name":"Global Market Access and Pricing  Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0671-0778","authenticated-orcid":false,"given":"Marc","family":"Evans","sequence":"additional","affiliation":[{"name":"Department of Medicine University Hospital Llandough  Cardiff UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klas","family":"Bergenheim","sequence":"additional","affiliation":[{"name":"Global Market Access and Pricing  Gothenburg Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7488-9058","authenticated-orcid":false,"given":"Phil","family":"McEwan","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Ltd  Cardiff UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,2,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-S081"},{"key":"e_1_2_7_3_1","unstructured":"Juvenile Diabetes Research Foundation. About Type 1 diabetes.https:\/\/jdrf.org.uk\/information-support\/about-type-1-diabetes\/Accessed August2018."},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2009.193"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1990"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2523"},{"key":"e_1_2_7_7_1","unstructured":"NHS Digital. National Diabetes Audit2016\u201017.https:\/\/digital.nhs.uk\/data-and-information\/clinical-audits-and-registries\/national-diabetes-audit. Accessed July 1 2019."},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-015-0297-x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0337-y"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2017.04.011"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004619"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13124"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0213-4"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0623"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30308-X"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1087"},{"key":"e_1_2_7_17_1","unstructured":"European Medicines Agency. Forxiga: EPAR \u2010 medicine overview.2019.https:\/\/www.ema.europa.eu\/en\/documents\/overview\/forxiga-epar-medicine-overview_en.pdf. Accessed September 1 2019."},{"key":"e_1_2_7_18_1","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal.2013.https:\/\/www.nice.org.uk\/process\/pmg9. Accessed July 1 2019."},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162441"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13590"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-015-0374-8"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291401"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052187"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1159\/000370271"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12080"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2114"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2011.03342.x"},{"key":"e_1_2_7_28_1","unstructured":"Office National Statistic. National life tables: England and Wales2015\u20132017.https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/datasets\/nationallifetablesenglandandwalesreferencetables. Accessed July 1 2019."},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.2337\/db18-119-LB"},{"key":"e_1_2_7_30_1","unstructured":"Diabetologia 2019 62 Long\u2010term efficacy and safety of dapagliflozin in patients with inadequately controlled type I diabetes \u2014 the DEPICT\u20102 study"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13863"},{"key":"e_1_2_7_32_1","unstructured":"Haymarket Media Group Ltd. Monthly Index of Medical Specialities.2018https:\/\/www.mims.co.uk\/. Accessed"},{"key":"e_1_2_7_33_1","unstructured":"CurtisL.Unit Costs of Health and Social Care 2017 Personal Social Services Research Unit (PSSRU).2017.https:\/\/doi.org\/10.22024\/UniKent\/01.02\/65559. Accessed July 1 2019."},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X16658660"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2005.01657.x"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12371"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/1932296818769098"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2014.971160"},{"key":"e_1_2_7_39_1","first-page":"183","article-title":"The economic burden and mortality of recurrent diabetic ketoacidosis: A 3 year cost analysis and mortality follow\u2010up at a district general hospital","volume":"33","author":"Byrne ML","year":"2016","journal-title":"Diabet Med"},{"key":"e_1_2_7_40_1","unstructured":"NICE. Type 1 diabetes in adults: diagnosis and management. Last updated July2016.https:\/\/www.nice.org.uk\/guidance\/ng17. Accessed July 1 2019."},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X115757"},{"key":"e_1_2_7_42_1","article-title":"Diabetic ketoacidosis in adults","volume":"351","author":"Misra S","year":"2015","journal-title":"BMJ: British Medical Journal"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.910"},{"key":"e_1_2_7_44_1","unstructured":"National Institute for Health and Care Excellence. NICE guidelines [NG17]. Type 1 diabetes in adults: diagnosis and management.2015.https:\/\/www.nice.org.uk\/guidance\/ng17. Accessed July 1 2019."},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcn125"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2014.04.007"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-015-1139-y"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12772"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13062"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1262-3636(14)72693-X"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2013.12.052"},{"key":"e_1_2_7_52_1","doi-asserted-by":"crossref","unstructured":"ChaplinS.SGLT2 inhibitors and risk of genitourinary infections. Prescriber.2016;27(12):26\u201030.","DOI":"10.1002\/psb.1521"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1884"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2886"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.03.009"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.029190"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.032038"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1210\/js.2019-SAT-LB025"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.13992","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.13992","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.13992","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:56:06Z","timestamp":1761868566000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.13992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,25]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1111\/dom.13992"],"URL":"https:\/\/doi.org\/10.1111\/dom.13992","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"type":"print","value":"1462-8902"},{"type":"electronic","value":"1463-1326"}],"subject":[],"published":{"date-parts":[[2020,2,25]]},"assertion":[{"value":"2019-10-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}